Katherine Stueland sold $3.0M of WGS
CHIEF EXECUTIVE OFFICER at GeneDx Holdings Corp.. 46,933 shares at an average of $63.17, traded Mar 26, 2026, filed Mar 30, 2026.
Score components
- +25RoleCEO
- +25Trade size$3.0M at market
- +10Share of holdings soldSold 34% of holdings
- +8Cluster2 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001689575-26-000021, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 26, 2026 | MOption exercise Class A Common Stock | +80,000 | $0.00 | $0 | 138,447 | Mar 30, 2026 |
| Mar 26, 2026 | SOpen-market sale Class A Common Stock | -13,229 | $61.29 | $811k | 125,218 | Mar 30, 2026 |
| Mar 26, 2026 | SOpen-market sale Class A Common Stock | -5,117 | $62.33 | $319k | 120,101 | Mar 30, 2026 |
| Mar 26, 2026 | SOpen-market sale Class A Common Stock | -13,412 | $63.28 | $849k | 106,689 | Mar 30, 2026 |
| Mar 26, 2026 | SOpen-market sale Class A Common Stock | -5,292 | $64.60 | $342k | 101,397 | Mar 30, 2026 |
| Mar 26, 2026 | SOpen-market sale Class A Common Stock | -9,883 | $65.21 | $645k | 91,514 | Mar 30, 2026 |
| Mar 26, 2026 | MOption exercise Restricted Stock Unitderivative | -80,000 | $0.00 | $0 | 160,000 | Mar 30, 2026 |
Related signals
Other insiders at GeneDx Holdings Corp. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 30Weak | GeneDx Holdings Corp. | Kevin Feeley CHIEF FINANCIAL OFFICER | $364k 3,728 shares | -8% | |
| 43Moderate | GeneDx Holdings Corp. | Katherine Stueland CHIEF EXECUTIVE OFFICER | $1.0M 10,501 shares | -8% | |
| 25Weak | GeneDx Holdings Corp. | Kevin Feeley CHIEF FINANCIAL OFFICER | $108k 1,285 shares | -3% | |
| 32Weak | GeneDx Holdings Corp. | Katherine Stueland CHIEF EXECUTIVE OFFICER | $311k 3,692 shares | -3% | |
| 20Weak | GeneDx Holdings Corp. | Kevin Feeley CHIEF FINANCIAL OFFICER | $31k 372 shares | -1% | |
| 39Weak | GeneDx Holdings Corp. | Kevin Feeley CHIEF FINANCIAL OFFICER | $557k 8,818 shares | -20% | |
| 37Weak | GeneDx Holdings Corp. | Kevin Feeley CHIEF FINANCIAL OFFICER | $438k 5,706 shares | -17% | |
| 48Moderate | GeneDx Holdings Corp. | Katherine Stueland CHIEF EXECUTIVE OFFICER | $1.3M 17,179 shares | -23% | |
| 25Weak | GeneDx Holdings Corp. | Kevin Feeley CHIEF FINANCIAL OFFICER | $111k 1,280 shares | -6% | |
| 32Weak | GeneDx Holdings Corp. | Katherine Stueland CHIEF EXECUTIVE OFFICER | $319k 3,678 shares | -8% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.